PZH2111

PZH2111 is an orally bioavailable small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family, specifically targeting FGFR1, FGFR2, and FGFR3. Developed by Zhangzhou Pientzehuang Pharmaceutical, the compound is designed to treat advanced solid tumors that harbor FGFR genetic alterations, such as gene fusions, mutations, or amplifications. FGFR signaling plays a critical role in cell proliferation, survival, and angiogenesis; its dysregulation is a known driver in several malignancies, including cholangiocarcinoma and urothelial carcinoma. PZH2111 is currently undergoing Phase 1 clinical evaluation to determine its safety, tolerability, and preliminary efficacy in patients with refractory solid tumors.